GRI Bio Announces Pricing of $5.0 Million Public Offering

Core Viewpoint - GRI Bio, Inc. has announced a public offering of common stock and warrants, aiming to raise approximately $5.0 million for product development and general corporate purposes [1][3]. Group 1: Offering Details - The public offering includes 1,388,888 shares of common stock and Series E-1, E-2, and E-3 warrants, all priced at $3.60 per share [1]. - The Series Warrants have an exercise price of $3.20 per share and will be exercisable immediately upon issuance, with varying expiration dates [1]. - The closing of the offering is expected around April 2, 2025, pending customary closing conditions [1]. Group 2: Financial Proceeds - The gross proceeds from the offering are estimated to be approximately $5.0 million before deducting fees and expenses [3]. - If fully exercised, the Series Warrants could provide an additional gross proceeds of approximately $13.3 million [3]. Group 3: Company Overview - GRI Bio is focused on developing therapies targeting Natural Killer T (NKT) cells for treating inflammatory, fibrotic, and autoimmune diseases [6]. - The lead program, GRI-0621, is an inhibitor of iNKT cell activity aimed at treating idiopathic pulmonary fibrosis [6]. - The company has a library of over 500 proprietary compounds to support its growing pipeline [6].